Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999673 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
A Phase 3 study, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 582
- Enrollment target
NCT01999673: Completed Phase 3 study, sponsored by Peregrine Pharmaceuticals.
NCT01999673 is a Phase 3 study that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 582 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01999673, a Phase 3 study, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 582 participants
- Enrollment target
Study Summary
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
Interventions
- DRUG Docetaxel
- BIOLOGICAL bavituximab
- OTHER Placebo (for bavituximab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
What the finished NCT01999673 record still lists
NCT01999673 is an interventional study that assigns participants to a tested intervention. The registered 582 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT01999673 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01999673 about?
NCT01999673 is a clinical study titled "Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer". The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
What is the current status of trial NCT01999673?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 582 participants. The study started on 2013-12. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01999673?
The interventions under investigation include: Docetaxel (DRUG), bavituximab (BIOLOGICAL), Placebo (for bavituximab) (OTHER).
Who is sponsoring clinical trial NCT01999673?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01999673's enrollment target sits among peer trials
582 653rd of 2000 higher than 1,345 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia